64.12.05

PTO/SB/30 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

work Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Request For Continued Examination (RCE) Transmittal

Address to: MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

09/058,589-Conf. #7637			
April 10, 1998			
Orla M. Conneely			
1617			
S. Wang			
HO-P02681US1			

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June

, 1995, of to any design application.							
1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).							
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.							
i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on							
ii. Other							
b. x Enclosed							
i. X Amendment/Reply iii. Information Disclosure Statement (IDS)							
ii. Affidavit(s)/Declaration(s) iv. Other							
2. Miscellaneous							
a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a							
period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)							
b. Other							
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.							
a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to							
Deposit Account No I have enclosed a duplicate copy of this sheet.							
i. X RCE fee required under 37 CFR 1.17(e)							
ii. Extension of time fee (37 CFR 1.136 and 1.17)							
iii. Other							
b. X Check in the amount of \$ 620.00 enclosed							
c. Payment by credit card (Form PTO-2038 enclosed)							
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED							
Signature Date April 11, 2005							
Name (Print/Type) Melisea W. Acesta Registration No. 45,872							

Reque	est for	Continued	Exam	ination	Transmitta
			- 110	D4-10	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV671532729US, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown

Dated: April 11, 2005

lau Harris) (Staci Harris)

APR 1 1 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service is Express Mail, Airbill No. EV671532729US, in an envelope addressed to 155 RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Signature:

Dated: April 11, 2005

Care Harrie

Docket No.: HO-P02681US1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Orla M. Conneely et al.

Application No.: 09/058,589

Art Unit: 1617

Filed: April 10, 1998

Examiner: S. Wang

For: LACTOFERRIN AS REGULATOR OF

ALLERGEN-INDUCED TUMOR NECROSIS

FACTOR-ALPHA PRODUCTION AND

THERAPEUTIC APPLICATIONS

AMENDMENT UNDER 37 CFR 1.114

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to Office Action dated November 16, 2004, please amend the aboveidentified U.S. patent application as follows:

Amendments to the Claims are reflected on page 2.

Remarks/Arguments begin on page 4 of this paper.